Texting to Reduce Human Immunodeficiency Virus (HIV) Risk

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBoston University

About this trial

This is a 3-year study to test the efficacy of a text message-based intervention program. Dental patients at 4 community health centers (n= 266) will be randomized to receive either text messages (TMs) regarding HIV prevention or TMs regarding overall wellness. Prior to enrolling the 266 participants, the investigators will conduct a feasibility pilot (n=20) to test the TM delivery as well as all study procedures. For both the pilot and the randomized clinical trial (RCT), recruitment will be conducted at 4 Community Health Center dental clinics (Codman Square, East Boston (both East Boston and South End locations), Geiger Gibson, and Upham's Community Health Centers). Recruitment materials (flyers and permission to contact forms) may also be made available at other clinics within the health centers.

The study will enroll English and Spanish-speaking patients who have at least one risk factor for HIV but are HIV-negative. Patients enrolled in the pilot will complete self-report surveys at baseline, 1 and 2 months. Participants enrolled in the RCT will complete self-report surveys baseline, 3, 6, and 12 months after baseline; receive and respond to TM assessments during the 6-month intervention.

Eligibility criteria

Qualifiers

Give informed consent and document consent via a signed and dated informed consent form in REDCap

Willing to comply with all study procedures and be available for the duration of the study

Be able to read either in English or Spanish

Be a dental clinic patient of record at one of our participating community health centers

Disqualifiers

Self-report of having HIV infection

Participating in another HIV study or another text message study

A woman who reports having sex exclusively with women

Does not have a mobile phone or other device which can receive text messages from Agile Health

Trial design

Treatments tested in this trial

  • TM HIV
  • TM HL

Treatment groups

266 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Boston University

Lead sponsor

National Institute of Dental and Craniofacial Research (NIDCR)

Collaborator